Researchers are developing a blood test that could detect whether a patient's cancer is returning, potentially revolutionizing follow-up care. The test, known as a liquid biopsy, analyzes circulating tumor DNA (ctDNA) in the bloodstream to identify signs of cancer recurrence months or even years before symptoms appear.
How the Technology Works
Liquid biopsies work by detecting tiny fragments of DNA shed by tumors into the blood. According to Dr. Sarah Thompson, an oncologist at the University of Toronto, “This approach allows us to monitor patients in real time without invasive biopsies. If we see ctDNA levels rise, it often means the cancer is coming back.” The test is already being studied in clinical trials for breast, lung, and colorectal cancers.
Current Research and Results
A recent study published in the New England Journal of Medicine found that liquid biopsies detected recurrence in 87% of patients with early-stage breast cancer, with an average lead time of 8 months before clinical symptoms. Researchers are now working to refine the test to reduce false positives and expand its use to other cancer types.
Implications for Patients
Early detection of recurrence could allow doctors to start treatment sooner, potentially improving survival rates. “This could transform how we follow up with cancer survivors,” said Dr. Thompson. “Instead of waiting for a lump or a scan, we can act on a blood test result.” However, experts caution that the test is not yet ready for widespread use and requires further validation.
